Pfizer Inc. (NYSE:PFE) Shares Bought by Indiana Trust & Investment Management CO

Indiana Trust & Investment Management CO increased its holdings in Pfizer Inc. (NYSE:PFE) by 2.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,934 shares of the biopharmaceutical company’s stock after purchasing an additional 400 shares during the quarter. Indiana Trust & Investment Management CO’s holdings in Pfizer were worth $470,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Mather Group LLC. raised its holdings in Pfizer by 35.0% during the 3rd quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock worth $1,133,000 after buying an additional 8,857 shares during the period. Samalin Investment Counsel LLC raised its holdings in shares of Pfizer by 8.2% during the third quarter. Samalin Investment Counsel LLC now owns 11,312 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 862 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Pfizer by 97.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 183,802 shares of the biopharmaceutical company’s stock valued at $6,097,000 after acquiring an additional 90,896 shares in the last quarter. Staley Capital Advisers Inc. boosted its stake in Pfizer by 4.3% in the 3rd quarter. Staley Capital Advisers Inc. now owns 1,346,187 shares of the biopharmaceutical company’s stock worth $44,653,000 after purchasing an additional 55,290 shares during the period. Finally, Bank of Nova Scotia grew its position in Pfizer by 219.4% during the 3rd quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock worth $182,567,000 after purchasing an additional 3,780,696 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.6 %

Shares of NYSE:PFE traded up $0.18 on Friday, reaching $27.98. The company had a trading volume of 33,156,727 shares, compared to its average volume of 40,908,660. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $158.55 billion, a P/E ratio of -467.09, a P/E/G ratio of 1.08 and a beta of 0.70. The stock has a 50-day moving average price of $27.81 and a 200 day moving average price of $27.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. The company’s revenue was down 19.5% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.